I am okay with the email part; since I only distribute custom editorials to my newsletter.
The snippet is the Signup card with the custom background and stuff. It rarely needs change. It does not need to be a Ghost Snippet, although preferred, but something that looks like that(and has the working sign-up functionality) but it has to be able to work with the HTML input to the Ghost API to create a new article.
Here is what I mean by HTML input:
<p>A research paper published in <strong>Aging</strong> explored the long-term consequences of lifesaving treatments such as hormone replacement therapy (HCT) and chemotherapy in breast cancer patients. These findings reveal significant impacts on the patients’ quality of life and longevity.</p> <h2>Treatment Comes at a Cost</h2> <p>HCTs and breast cancer treatments, while essential, come with side effects. For instance, <em>chemotherapy</em> sharply increases <strong>p16INK4a</strong>, a key biomarker of cellular senescence, whereas HCTs have been linked to <strong>accelerated aging</strong>. Consequently, individuals undergoing such treatments may develop frailty, exhibiting physical abilities similar to those of older individuals. Several symptoms were documented, such as:</p> <ul> <li><strong>Constant exhaustion</strong>: Reported by over 75% of patients.</li> <li><em>Unintentional significant weight loss</em>: On average, a reduction of <strong>7%</strong> body weight over 6 months.</li> <li>Slow walking speed: Gait speed reduction of <em>20%</em> compared to healthy peers.</li> <li>Limited physical activity: A <strong>40%</strong> decrease in weekly exercise routines.</li> <li>Poor grip strength: A key marker of physical frailty and loss of muscle mass.</li> </ul> <p>Patients who demonstrated one or two of these symptoms were deemed <strong>pre-frail</strong>, while those who exhibited three or more were classified as <strong>physically frail</strong>.</p> <h2>Impact on Quality of Life and Longevity</h2> <p>The impact of these treatments is multifaceted, affecting both the physical and emotional well-being of patients. Below is a breakdown of some of the research findings:</p> <table> <thead> <tr> <th>Aspect</th> <th>Findings</th> <th>Source</th> </tr> </thead> <tbody> <tr> <td>Frailty Markers</td> <td>Elevated levels of p16INK4a, indicating biological aging.</td> <td>Study 1</td> </tr> <tr> <td>Quality of Life (QoL)</td> <td>Significant decline in physical, emotional, and social well-being.</td> <td>Study 2</td> </tr> <tr> <td>Mortality Risk</td> <td>Heightened risk of early mortality associated with frailty.</td> <td>Study 3</td> </tr> </tbody> </table> <h2>Associations Between Treatment and Aging</h2> <p>The relationship between <strong>frailty</strong> and treatment is complex, with various contributing factors:</p> <table> <thead> <tr> <th>Factor</th> <th>Correlation with Frailty</th> </tr> </thead> <tbody> <tr> <td>Age at Diagnosis</td> <td>Older patients exhibit a higher level of frailty.</td> </tr> <tr> <td>Treatment Duration</td> <td>Longer treatments correlate with increased frailty.</td> </tr> <tr> <td>Type of Therapy</td> <td>Patients undergoing HCT have a greater risk of frailty compared to those receiving chemotherapy.</td> </tr> </tbody> </table> <ul> <li><strong>Chronological Age vs. Biological Age</strong>: While chronological age is a predictor, <em>biological markers</em> like <strong>p16INK4a</strong> serve as better indicators of frailty.</li> <li><em>Length of Time Since Treatment</em>: Those treated within the last 3-5 years show higher levels of frailty.</li> <li><strong>Therapy Type</strong>: Chemotherapy and HCT show distinct correlations with biological aging, with HCT being more associated with greater frailty.</li> </ul> <blockquote> “The acceleration of biological aging resulting from these treatments necessitates the development of new approaches that mitigate long-term harm while preserving the lifesaving benefits.” – Dr. John Smith, Lead Researcher </blockquote> <h2>Future Directions</h2> <p>To improve patient outcomes, researchers emphasize the need for treatments that minimize adverse effects. Current studies focus on:</p> <ul> <li>Developing <strong>less aggressive chemotherapy protocols</strong> that reduce senescent cell burden.</li> <li>Incorporating <strong>lifestyle interventions</strong> such as exercise, nutrition, and stress management to lower frailty risk.</li> <li>Utilizing <strong>biomarkers like p16INK4a</strong> to identify patients at higher risk of accelerated aging due to treatment.</li> </ul> <p>Balancing <em>treatment efficacy</em> with <em>patient quality of life</em> is critical in reducing the long-term negative impacts of these cancer therapies.</p> <hr /> <h3>Literature Cited</h3> <p>[1] Shachar, S. S., et al. (2020). Effects of breast cancer adjuvant chemotherapy on aging biomarkers. JNCI Cancer Spectrum.</p> <p>[2] Uziel, O., et al. (2020). Premature aging following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation.</p> <p>[3] Ness, K. K., et al. (2013). Physiologic frailty and aging in cancer survivors. Journal of Clinical Oncology.</p> <p>[4] Arora, M., et al. (2016). Frailty in nonelderly transplant patients. JAMA Oncology.</p>
This is passed into the Ghost API to create a new article(see picture below):
Also, thank you for taking the time to help me with this
